Seminars in Nuclear Medicine
Volume 31, Issue 4 , Pages 296-311 , October 2001

Radiolabeled peptides in diagnosis and therapy

  • Ronald E. Weiner

      Affiliations

    • Department of Diagnostic Imaging and Therapeutics, University of Connecticut Health Center, Farmington, CT USA
    • Department of Radiology, Thomas Jefferson University Hospital, Philadelphia, PA, USA
    • Corresponding Author InformationAddress reprint requests to Ron Weiner, PhD, University of Connecticut Health Center, Division of Nuclear Medicine MC-2804, 263 Farmington Ave, Farmington, CT 06030.
    • ,
  • Mathew L. Thakur

      Affiliations

    • Department of Diagnostic Imaging and Therapeutics, University of Connecticut Health Center, Farmington, CT USA
    • Department of Radiology, Thomas Jefferson University Hospital, Philadelphia, PA, USA

References 

  1. OncoScint, Package insert. Princeton, NJ: Cytogen; 1992;
  2. Hnatowich DJ. Antibody radiolabeling: Problems and promises. Nuc Med Biol. 1990;17:49–55
  3. Okarvi SM. Recent developments in 99mTc-labelled peptide-based radiopharmaceuticals. An overview: Nucl Med Commun. 1999;20:1093–1112
  4. McGilvery RW. In: ed 3. Biochemistry: A Functional Approach. Philadelphia: Saunders; 1983;p. 18–23
  5. Dean RT, James JL, Lees RS, et al. Peptides in biomedical sciences: Principles and practice. In: Martin-Comin J, Thakur ML, Piera C, et al. editor. Radiolabeled Blood Elements. New York: Plenum Press; 1994;p. 195–199
  6. Thakur ML. Radiolabelled peptides: Now and the future. Nuc Med Commun. 1995;16:724–732
  7. McAfee JG, Neumann RD. Radiolabeled peptides and other ligands for receptors overexpressed in tumor cells for imaging neoplasms. Nucl Med Biol. 1996;23:673–676
  8. Raidoo KE, Lin K-S, Zhan Y, et al. Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconjugate Chem. 1998;10:218–225
  9. OctreoScan, Package insert. St Louis, MO: Mallinckrodt; 1994;
  10. Pallela VR, Thakur ML, Chakder S, et al. 99mTc-labeled vasoactive intestinal peptide receptor agonist. Functional studies. J Nucl Med. 1999;40:352–360
  11. Thakur ML, Marcus CS, Saeed S, et al. 99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. J Nucl Med. 2000;41:107–110
  12. Thakur ML. Scintigraphic imaging of venous thrombosis: The state of the art. Thromb Haemorrh Disorders. 1992;5:29–36
  13. Loscalzo J, Rocco TP. Imaging arterial thrombi: An elusive goal. Circulation. 1992;85:382–385
  14. Som P, Oster ZH. Thrombus-specific imaging: Approaching the elusive goal. J Nucl Med. 1994;35:202–203
  15. Haines ST, Bussey HI. Thrombosis and the pharmacology of antithrombotic agents. Ann Pharmacother. 1995;29:892–904
  16. Blockmans D, Deckmyn H, Vermylen J. Platelet activation. Blood Rev. 1995;9:143–156
  17. Guyton AC. In: ed 8. Textbook of Medical Physiology. Philadelphia: Saunders; 1991;p. 365–373
  18. Anderson RE, Hill B, Key CR. The sensitivity and specificity of clinical diagnostics during five decades. JAMA. 1989;261:1610–1617
  19. Koblink PD, DeNardo GL, Berger HJ. Current status of immunoscintigraphy in the detection of thrombosis and thromboembolism. Semin Nucl Med. 1989;19:221–231
  20. Moser KM. Venous thromboembolism. Am Rev Respir Dis. 1990;141:235–249
  21. Hull RD, Hirsh J, Carter CJ, et al. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med. 1983;98:891–899
  22. Lensing AWA, Prandoni P, Brandjes D, et al. Detection of deep-vein thrombosis by real-time b-mode ultrasonography. N Engl J Med. 1989;320:342–345
  23. Davidson BL, Elliott CG, Lensing AWA. Low accuracy of color doppler ultrasound in the detection of proximal leg vein thrombosis in asymptomatic high-risk patients. Ann Intern Med. 1992;117:735–738
  24. Rose SC, Swiebel WJ, Nelson BD, et al. Symptomatic lower extremity deep venous thrombosis: Accuracy, limitations, and role of color duplex flow imaging in diagnosis. Radiology. 1990;175:639–644
  25. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Circulation. 1996;15:2212–2245
  26. Knight LC. Radiopharmaceuticals for thrombus detection. Semin Nucl Med. 1990;20:52–67
  27. Ezekowitz MD, Dey HM, Thakur ML. Radionuclide-based imaging techniques for thrombus detection. In: Ezekowitz MD editors. Systemic Cardiac Embolism. New York: Marcel Dekker, Inc.; 1994;p. 165–180
  28. (abstr) Seabold JE, Tulchinsky M, Edell SL, et al. 99mTc DMP-444 peptide scintigraphy for detection of acute deep vein thrombosis (DVT)-A multicenter clinical trial. J Nucl Med. 2000;41:12P
  29. (abstr) Taillefer R, Barnes D, Hill J, et al. 99mTc-FBD (fibrin binding domain of Fibronectin) scintigraphy in patients with acute dep vein thrombosis (ADVT) Results of the phase II multicenter trial. J Nucl Med. 2000;12P
  30. Taillefer R, Thérasse E, Turpin S, et al. Comparison of early and delayed scintigraphy with 99mTc-Apcitide and correlation with contrastenhanced venography in detection of acute deep vein thrombosis. J Nucl Med. 1999;40:2029–2035
  31. Acu Tect Package insert. Londonderry: Diatide; 1998;
  32. (abstr) Easton EJ. Acu Tect and pulmonary embolisms. J Nucl Med. 1999;40:11P
  33. (abstr) Line BR, Crane P, Lazewatsky J, et al. Phase I trial of DMP 444, a new thrombus imaging agent. J Nucl Med. 1996;37:117P
  34. (abstr) Lazewatsky J, Line B, Barrett J, et al. Radiation dosimetry estimates in nonhuman primates and humans for DMP444, a new thrombus-imaging agent. J Nucl Med. 1996;35:232P
  35. (abstr) Seabold JE, Salisbury SM, Edell SL, et al. Does heparin therapy affect the results of Tc-99m DMP-444 scintigraphy for detection of acute deep vein thrombosis (DVT)?. J Nucl Med. 1999;40:152P
  36. (abstr) Borg BD, Tulchinsky M, Pellegrini VD. Detection of deep venous thrombosis by thromboscintigraphy with DMP-444 after total knee arthroplasty. J Nucl Med. 2000;41:12P
  37. Knight LC, Maurer AH, Romano JE. Comparison of iodine-123-disintegrins for imaging thrombi and emboli in a canine model. J Nucl Med. 1996;37:476–482
  38. Knight LC, Baidoo DE, Romano J, et al. Imaging pulmonary emboli and deep venous thrombi with 99Tc-bitistatin, a platelet-binding polypeptide from viper venom. J Nucl Med. 2000;41:1056–1064
  39. (abstr) Knight LC, Baidoo KE, Romano JE, et al. Production of recombinant bitistatin and comparison with native bitistatin for imaging thrombi and emboli. Nucl Med Commun. 2000;21:573
  40. Ezov N, Nimrod A, Parizada B, et al. Recombinant polypeptides derived from the fibrin-binding domain of fibronectin are potential agents for the imaging of blood clots. Thromb Haemost. 1997;77:796–803
  41. Thakur ML, Pallela VR, Consigny PM, et al. Imaging vascular thrombosis with 99mTc-labeled fibrin α-chain peptide. J Nucl Med. 2000;41:161–168
  42. Coleman RE, Datz FL. Detection of inflammatory disease using radiolabeled cells. In: Sandler MP, Coleman RE, Wackers F, et al. editor. Diagnostic Nuclear Medicine. ed 3. Baltimore: Williams & Wilkins; 1996;p. 1509–1524
  43. Peters AM. Imaging inflammation: Current role of labeled autologous leukocytes. J Nucl Med. 1992;33:65–67
  44. Reynolds JH, Graham D, Smith FW. Imaging inflammation with 99mTc-HMPAO labelled leucocytes. Clin Radiology. 1990;42:195–198
  45. Becker W, Schomann E, Fischback W, et al. Comparison of 99mTc-HMPAO and 111In-oxine labeled granulocytes in man: First clinical results. Nucl Med Commun. 1988;9:435–447
  46. Moyer BR, Vallabhajosula S, Lister-James J, et al. Technetium-99m-white blood cell-specific imaging agent developed from platelet factor 4 to detect infection. J Nucl Med. 1996;37:673–679
  47. (abstr) Palestro CJ, Tomas MB, Bhargava KK, et al. Tc-99m P483H for imaging infection: Phase 2 multicenter trial results. J Nucl Med. 1999;40:15P
  48. Caveliers V, Goodbody AE, Tran LL, et al. Evaluation of 99mTc-RP128 as a potential inflammation imaging agent: Human dosimetry and first clinical results. J Nucl Med. 2001;42:154–161
  49. (abstr) Iles DL, Goodbody AE, Cockeram A, et al. A pilot phase II clinical study on imaging inflammatory lesions in patients with Crohn's disease using Tc-99m RP128. J Nucl Med. 1998;39:271P
  50. (abstr) Zoghbi SS, Thakur ML, Gottschalk A, et al. Selective cell labeling: A potential radioactive agent for labeling human neutrophils. J Nucl Med. 1981;22:32P
  51. Fischman AJ, Babich JW, Rubin RH. Infection imaging with technetium-99m-labeled chemotactic peptide analogs. Semin Nucl Med. 1994;24:154–168
  52. Fischman AJ, Rauh D, Solomon H, et al. In vivo bioactivity and biodistribution of chemotactic peptide analogs in nonhuman primates. J Nucl Med. 1993;34:2130–2134
  53. Babich JW, Grahan W, Barrow SA, et al. Technetium-99m-labeled chemotactic peptides comparison with indium-111-labeled white blood cells for localizing acute bacterial infection in the rabbit. J Nucl Med. 1993;34:2176–2181
  54. Babich JW, Solomon H, Pike MC, et al. Technetium-99m-labeled hydrazino nicotinamide derivatized chemotactic peptide analogs for imaging focal sites of bacterial infection. J Nucl Med. 1993;34:1964–1974
  55. (abstr) Babich JW, Dong Q, Graham W, et al. N,N-Bis(2-mercaptoethyl)methylamine (NS2): A new co-ligand for Tc-99m labeling of hydrazinonicotinamine (HYNIC) peptides. J Nucl Med. 1997;38:188P
  56. Derian CK, Solomon HF, Higgins JD, et al. Selective inhibition of N-formylpeptide-induced neutrophil activation by carbamate-modified peptide analogues. Biochemistry. 1966;35:1265–1269
  57. Baidoo KE, Scheffel U, Stathis M, et al. High-affinity no-carrier-added 99mTc-labeled chemotactic peptides for studies of inflammation in vivo. Bioconjugate Chem. 1998;9:208–217
  58. van der Laken CJ, Boerman OC, Oyen WJG, et al. Technetium-99m-labeled chemotactic peptide in acute infection and sterile inflammation. J Nucl Med. 1997;38:1310–1315
  59. Rao PS, Pallela VR, Belnikolavska DV, et al. A receptor-specific peptide for imaging infection and inflammation. Nucl Med Commun. 2000;21:1063–1070
  60. Barrett JA, Crocker AC, Damphousse DJ, et al. Biological evaluation of thrombus imaging agents utilizing water soluble phosphines and tricine as coligands when used to label a hydrazinonicotinamide-modified cyclic glycoprotein IIb/IIIa receptor antagonist with 99mTc. Bioconjugate Chem. 1997;8:155–160
  61. Welling MM, Hiemstra PS, van den Barselaar MT, et al. Antibacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leukocyte accumulation. J Clin Inv. 1998;102:1583–1590
  62. Welling MM, Nibbering PH, Paulusma-Annema A, et al. Imaging of bacterial infections with 99mTc-labeled human neutrophil peptide-1. J Nucl Med. 1999;40:2073–2080
  63. Welling MM, Paulusma-Annema A, van den Barselaar MT, et al. Radiolabelled antimicrobial peptides distinguish between infections and inflammatory processes. Nuc Med Commun. 2000;21:582
  64. Hancock REW, Scott MG. The role of antimicrobial peptides in animal defenses. Proc Natl Acad Sci USA. 2000;97:8856–8861
  65. (abstr) Nibbering PH, Welling MM, Paulusma-Annema A, et al. Monitoring the efficacy of antibacterial treatments of infections with Tc-99m-labeled antimicrobial peptides. Nucl Med Commun. 2000;21:575–576
  66. (abstr) Lupetti A, Welling MM, Paulusma-Annema A, et al. Imaging of infections with Candida albicans with 99mTc-labelled antimicrobial peptides and the antifungal agent fluconazole. Nucl Med Commun. 2000;21:573–574
  67. Rusckowski M, Qu T, Pullman J, et al. Inflammation and infection imaging with a 99mTc-neutrophil elastase inhibitor in monkeys. J Nucl Med. 2000;41:363–374
  68. Qu T, Wang Y, Zhu Z, et al. Different chelators and different peptides together influence the in vivo properties of 99mTc. Nucl Med Commun. 2001;22:203–215
  69. Krenning EP, Kwekkeboom DJ, Pauwels S, et al. Somatostatin receptor scintigraphy. Nucl Med Ann. 1995;1–50
  70. van Eijck CH, de Jong M, Breeman WA, et al. Somatostatin receptor imaging and therapy of pancreatic endocrine tumors. Ann Oncol. 1999;10:1777–1781
  71. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med. 2000;41:1704–1713
  72. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1] and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1,000 patients. Eur J Nucl Med. 1993;20:716–731
  73. Krenning EP, Bakker WH, Breeman WA, et al. Localization of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989;4:242–244
  74. Lamberts SWJ, Krenning E, Reubi J-C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Rev. 1991;12:450–482
  75. Gibril F, Reynolds JC, Chen CC, et al. Specificity of somatostatin receptor scintigraphy: A prospective study and effects of false-positive localization on management in patients with gastrinomas. J Nucl Med. 1999;40:539–553
  76. Nilsson O, Kölby L, Wängberg B, et al. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer. 1998;77:632–637
  77. Breeman WAP, van Hagen PM, Kwekkeboom DJ, et al. Somatostatin receptor scintigraphy using [111In-DTPA0]RC-160 in humans: A comparison with [111In-DTPA0]octreotide. Eur J Nucl Med. 1998;25:182–186
  78. Reubi JC, Horisberger U, Laissue J. High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumor-host interaction?. Int J Cancer. 1994;56:681–688
  79. Lugtenburg PJ, Löwenberg B, Valkema R, et al. Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin's lymphomas. J Nucl Med. 2001;42:222–229
  80. Flamen P, Bossuyt A, De Greve J, et al. Imaging of renal cell cancer with radiolabeled Octreotide. Nuc Med Commun. 1993;14:873–877
  81. Lipp RW, Silly H, Ranner G, et al. Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy. J Nucl Med. 1995;36:13–18
  82. van Eijck CHJ, Krenning EP, Bootsma A, et al. Somatostatinreceptor scintigraphy in primary breast cancer. Lancet. 1994;343:640–643
  83. Lebtahi R, Crestani B, Belmatoug N, et al. Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis. J Nucl Med. 2001;42:21–26
  84. Kwekkeboom DJ, Krenning EP, Kho GS, et al. Somatostatin receptor imaging in patients with sarcoidosis. Eur J Nucl Med. 1998;25:1284–1292
  85. Weinmann P, Crestani B, Tazi A, et al. 111In-pentetreotide scintigraphy in patients with Langerhans' cell histiocytosis. J Nucl Med. 2000;41:1808–1812
  86. Kvols LK. Somatostatin-receptor imaging of human malignancies: A new era in the localization, staging, and treatment of tumors. Gastroenterology. 1993;105:1909–1914
  87. Forsell-Aronsson EB, Nilsson O, Benjegård SA, et al. 111In-DTPA-D-Phe1 Octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med. 2000;41:636–642
  88. Chiti A, Briganti V, Fanti S, et al. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours. Q J Nucl Med. 2000;44:42–49
  89. Kirsch C-M, von Pawel J, Grau I, et al. Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma. Eur J Nucl Med. 1994;21:1318–1325
  90. O'Byrne KJ, Halmos G, Pinski J, et al. Somatostatin receptor expression in lung cancer. Eur J Cancer. 1994;30A:1682–1687
  91. Kwekkeboom DJ, Kho GS, Lamberts SWJ, et al. The value of Octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med. 1994;21:1106–1113
  92. Bomardieri E, Crippa F, Cataldo I, et al. Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of 111In-DTPA octreotide scintigraphy. Eur J Cancer. 1995;31A:184–188
  93. Stokkel MPM, Pauwels EKJ. Octreotide scintigraphy for small cell lung carcinoma: Past, present or future?. Eur J Nucl Med. 1994;21:1276–1278
  94. Blum JE, Handmaker H, Rinne NA. The utility of a somatostatin-type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules. Chest. 1999;115:224–232
  95. Valk PE, Pounds TR, Tesar RD, et al. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol. 1996;23:737–743
  96. NeoTect, Package insert. Londonderry: Diatide; 1999;
  97. Virgolini I, Leimer M, Handmaker H, et al. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829. Cancer Res. 1998;58:1850–1859
  98. Virgolini I, Kurtaran A, Raderer M, et al. Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med. 1995;36:1732–1739
  99. Reubi JC. In vitro identification of vasoactive intestinal peptide receptors in human tumors: Implications for tumor imaging. J Nucl Med. 1995;36:1846–1853
  100. Raderer M, Kurtaran A, Yang Q, et al. Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer. J Nucl Med. 1998;39:1570–1575
  101. Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med. 1994;331:1116–1121
  102. Raderer M, Kurtaran A, Leimer M, et al. Value of peptide receptor scintigraphy using 123I-vasoactive intestinal peptide and 111In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University experience 1993 to 1998. J Clin Onc. 2000;18:1331–1336
  103. Raderer M, Becherer A, Kurtaran A, et al. Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy. J Nucl Med. 1996;37:1480–1487
  104. Thakur ML, Marcus CS, Saeed S, et al. Imaging tumors in humans with Tc-99m-VIP. Ann N Y Acad Sci. 2000;921:37–44
  105. 244P Virgolini I, Traub T, Ofluoglu S, et al. Human biodistribution, safety and absorbed dose of 99mTc-1666 vasoactive intestinal peptide (VIP) receptor scintigraphy. (abstr) J Nucl Med. 1999;40:
  106. (abstr) Behr TM, Béhé , Angerstein C, et al. Development of cholecystokinin-B/gastrin-receptor binding peptides for diagnosis and therapy: Results of a clinical phase-I/II study for the staging of known and occult metastatic medullary thyroid cancer. Nucl Med Commun. 2000;21:564–565
  107. Behr TM, Jenner N, Radetzky S, et al. Targeting of cholecystokinin-B/gastrin receptors in vivo: Preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med. 1998;25:424–430
  108. Behr TM, Jenner N, Béhé M, et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med. 1999;40:1029–1044
  109. de Jong M, Bakker WH, Bernard BF, et al. Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: A peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med. 1999;40:2081–2087
  110. Reubi JC, Schaer J-C, Waser B. Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 1997;57:1377–1386
  111. Karra SR, Schibli R, Gali H, et al. 99mTc-labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine-based bifunctional chelating agent. Bioconjugate Chem. 1999;10:254–260
  112. Breeman WA, de Jong M, Bernard BF, et al. Pre-clinical evaluation of [(111)In-DTPA-Pro(1), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer. 1999;83:657–663
  113. Reilly RM, Kiarash R, Cameron RG, et al. In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J Nucl Med. 2000;41:429–438
  114. Capala J, Barth RF, Bailey MQ, et al. Radiolabeling of epidermal growth factor with 99m-Tc and in vivo localization following intracerebral injection into normal and glioma-bearing rats. Bioconjugate Chem. 1997;8:289–295
  115. Rusckowski M, Qu T, Chang F, et al. Technetium-99m labeled epidermal growth factor-tumor imaging in mice. J Pept Res. 1997;50:393–401
  116. Rémy S, Reilly RM, Sheldon K, et al. A new radioligand for the epidermal growth factor receptor: 111In-labeled human epidermal growth factor derivatized with a bifunctional metal-chelating peptide. Bioconjug Chem. 1995;6:683–690
  117. Reilly RM, Kiarash R, Sandhu J, et al. A comparison of EGF and MAb528 labeled with 111In for imaging human breast cancer. J Nucl Med. 2000;41:903–911
  118. Jenkins SA, Kynaston HG, Davies ND, et al. Somatostatin analogs in oncology: A look to the future. Chemotherapy. 2001;47:162–196
  119. Wiseman GA, White CA, Stabin M, et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refrac-tory non-Hodgkin's lymphoma. Eur J Nucl Med. 2000;27:766–777
  120. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259–1266
  121. Silvester J. Consequences of indium-111 decay in vivo: Calculated absorbed radiation dose to cells labeled by indium-111 oxine. J Lab Comp Radiopharm. 1978;19:196–197
  122. Gardin I, Faraggi M, Le Guludec D, et al. Cell irradiation caused by diagnostic nuclear medicine procedures: Dose heterogeneity and biological consequences. Eur J Nucl Med. 1999;26:1617–1626
  123. Andersson P, Forssell-Aronsson E, Johanson V, et al. Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide. J Nucl Med. 1996;37:2002–2006
  124. Janson ET, Westlin J-E, Ohrvall U, et al. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-Octreotide in patients with neuroendocrine tumors. J Nucl Med. 2000;41:1514–1518
  125. Hornick CA, Anthony CT, Hughey S, et al. Progressive nuclear translocation of somatostatin analogs. J Nucl Med. 2000;41:1256–1263
  126. (abstr) Buscombe JR, Caplin ME, Hilson AJW. Treating disseminated NETs with high activity In-111 Octreotide. Nuc Med Commun. 2000;21:567
  127. de Jong M, Breeman WA, Bernard HF, et al. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues. Q J Nucl Med. 1999;43:356–366
  128. McCarthy KE, Woltering EA, Anthony LB. In situ radiotherapy with 111-In-pentetreotide. State of the art and perspectives. Q J Nucl Med. 2000;44:88–95
  129. abstr 2748 Argiris A, Peccerillo K, Murren JR, et al. Phase I/II trial with 111-In-pentetreotide in patients with advanced malignancies. In: Poster presentation at the Digestive Disease Week. 2000;
  130. McCarthy KE, Woltering EA, Espenan GD, et al. In situ radiotherapy with 111In-pentetreotide: Initial observations and future directions. Cancer J Sci Amer. 1998;4:94–102
  131. 18P Cornelius EA, Murren J, Zoghbi S, et al. In-111-octreotide therapy: Phase I–II trial. (abstr) J Nucl Med. 1999;40:
  132. Albert R, Smith-Jones P, Stolz B, et al. Direct synthesis of [DTOA-Dphe1-Tye3]-Octreotide (SMT487): Two conjugates for the systemic delivery of radiotherapeutical nuclides to somatostatin receptor-positive tumors in man. Bioorg Med Chem Lett. 1998;8:1207–1210
  133. Otte A, Jermann E, Behe M, et al. DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med. 1997;24:792–795
  134. Otte A, Mueller-Brand J, Dellas S, et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 1998;351:417–418
  135. Rosch F, Herzog H, Stolz B, et al. Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-Dphel-Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue. Eur J Nucl Med. 1999;26:358–366
  136. 18P Chinol M, Paganelli G, Zoboli S, et al. 90Y-DOTATOC treatment of patients with SSTR2-positive tumors: Preliminary results of phase I–II study. (abstr) J Nucl Med. 1999;40:
  137. (abstr) Paganelli G, Zoboli S, Cremonesi M, et al. Receptor-mediated radiotherapy with 90Y-DOTATOC: Towards the right dose. Nucl Med Commun. 2000;21:562
  138. Smith MC, Liu J, Chen T, et al. OctreoTher: Ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy. Digestion. 2000;62:69–72
  139. Smith-Jones PM, Bischof C, Leimer M, et al. DOTA-lanreotide: A novel somatostatin analog for tumor diagnosis and therapy. Endocrinology. 1999;140:5136–5148
  140. (abstr) Goldsmith SJ, Kostakoglu L, Smith-Jones P, et al. 90Y-DOTA-lanreotide: Dosimetry and toxicity. Nucl Med Commun. 2000;21:588
  141. (abstr) Britton KE, Foley RR, Barlow R, et al. Early experience with Y-90 lanreotide therapy. Nucl Med Commun. 2000;21:567
  142. Anderson CJ, Dehdashti F, Cutler PD, et al. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med. 2001;42:213–221
  143. Reubi JC. Neuropeptide receptors in health and disease. The molecular basis for in vivo imaging. J Nucl Med. 1995;36:1825–1835
  144. Reubi JC. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med. 1997;41:63–70
  145. Heasly LE. Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene. 2001;20:1563–1569
  146. Weiner RE, Thakur ML: Chemistry of gallium and indium radiopharmaceuticals, in Welch M. Redvanly C (eds): Handbook of Radiopharmaceuticals: Radiochemistry and Applications. West Sussex, John Wiley Publishers (in press)

PII: S0001-2998(01)80009-X

doi: 10.1053/snuc.2001.27045

Seminars in Nuclear Medicine
Volume 31, Issue 4 , Pages 296-311 , October 2001

Article Tools